In their effort to answer a decades-old biological question about how the hepatitis B virus (HBV) is able to establish infection of liver cells, research led by Memorial Sloan Kettering Cancer Center ...

In their effort to answer a decades-old biological question about how the hepatitis B virus (HBV) is able to establish ...

We expect investors to focus on the sales performance of ADMA Biologics’ ADMA portfolio of marketed products and other ...

Excessive alcohol use can harm the body in many ways, including an increase in the risk of various cancers. It damages liver ...

Assessment of liver fibrosis and cirrhosis is crucial for the management of patients with chronic hepatitis B. The presence of at least moderate liver fibrosis is an important indication for antiviral ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2024. "Gilead delivered another exceptionally ...

With several drugs in use that inhibit the hepatitis B virus polymerases (nucleos(t)ide analogues (or NUCs)), some argue that new direct-acting antiviral drugs, and new NUCs in particular ...

A recent study from Temple University finds a majority of Pennsylvania college students consider themselves educated about ...

Investors' focus will likely be on GILD's HIV franchise performance and oncology sales when the company reports ...

but one hepatitis C study, which recruited homeless individuals from shelters, special projects and medical centres in Oxford, found 26.5% of individuals positive using oral fluid testing.25 Our ...

However, with the widespread use of PD-1 inhibitors, there are increasing reports of immune-related adverse events (irAEs) in clinical practice, with immune-related hepatitis (IRH ... revealing the ...